<DOC>
	<DOC>NCT02544152</DOC>
	<brief_summary>A study of the efficacy and safety of Lubiprostone in subjects diagnosed with IBS-M/IBS-U.</brief_summary>
	<brief_title>Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome</brief_title>
	<detailed_description>To assess the efficacy and safety of oral lubiprostone, as compared to matching placebo, when administered orally (at 8 mcg twice daily [BID]) in subjects diagnosed with IBS-M/IBS-U.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>Subject meets the diagnosis of IBSM or IBSU as confirmed using the adapted ROME III Diagnostic Questionnaire for Adult Functional GI Disorders. Subject Screening diary entries must show an average worst abdominal pain in the past 24 hours score of at least 4 on a 11point scale. Subject must be on a stable dose of selective serotonin reuptake inhibitors (SSRIs), serotoninspecific reuptake inhibitor (SNRIs), or monoamine oxidase inhibitors (MAO) inhibitors if taking antidepressants. Subject has current diagnosis of IBS with diarrhea (IBSD) or IBS with constipation (IBSC), according to Rome III Criteria. Any gastrointestinal (GI) condition, other than IBSrelated, affecting GI motility or defecation. Medical/surgical condition that might interfere with the absorption, distribution, metabolism, or excretion of the study medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>